Evidence map›Paper›PMID 32276665›Full record

ArticleOrphanet journal of rare diseases2020

The French national protocol for Kennedy's disease (SBMA): consensus diagnostic and management recommendations.

Pierre-François Pradat, Emilien Bernard, Philippe Corcia, Philippe Couratier, Christel Jublanc, Giorgia Querin, Capucine Morélot Panzini, François Salachas, Christophe Vial, Karim Wahbi and 3 more

Open access · goldAbstract readConsensus Statement
In one paragraph

Article in Orphanet journal of rare diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 4 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026
    Guideline
  3. Best practice recommendations for the clinical care of spinal bulbar muscular atrophy.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  4. Pooled it
  5. Mexiletine in spinal and bulbar muscular atrophy: a randomized controlled trial.Annals of clinical and translational neurology · 2022
    Trial
  6. Article
  7. Frequency and Circumstances of Falls Events in People Living With Spinal and Bulbar Muscular Atrophy: A Cross-Sectional Survey.Physiotherapy research international : the journal for researchers and clinicians in physical therapy · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 3 countries.

Pierre-François PradatAP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Département de Neurologie, Centre de Reference pour la SLA et les Maladies du Motoneurone, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, 47 Boulevard de l'Hôpital - F-75634, 13, Paris Cedex, France. pierre-francois.pradat@psl.aphp.fr.
Emilien BernardService d'électromyographie et pathologies neuromusculaire, Centre de Reference pour la SLA et les Maladies du Motoneurone, CHU Lyon Hôpital Neurologique P. Wertheimer, Lyon, France.
Philippe CorciaDépartement de Neurologie, Centre de Reference pour la SLA et les Maladies du Motoneurone, CHU Tours, Tours, France.
Philippe CouratierDépartement de Neurologie, Centre de Reference pour la SLA et les Maladies du Motoneurone, CHU Limoges, Limoges, France.
Christel JublancAP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière Département d'endocrinologie, Paris, France.
Giorgia QuerinAP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Département de Neurologie, Centre de Reference pour la SLA et les Maladies du Motoneurone, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, 47 Boulevard de l'Hôpital - F-75634, 13, Paris Cedex, France.
Capucine Morélot PanziniAP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), F-75013, Paris, France.
François SalachasAP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Département de Neurologie, Centre de Reference pour la SLA et les Maladies du Motoneurone, Paris, France.
Christophe VialService d'électromyographie et pathologies neuromusculaire, Centre de Reference pour la SLA et les Maladies du Motoneurone, CHU Lyon Hôpital Neurologique P. Wertheimer, Lyon, France.
Karim WahbiAP-HP, CHU Cochin, Service de cardiologie, Centre de référence des maladies neuromusculaires Nord/Est/Ile de France, Paris, France.
Peter BedeAP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Département de Neurologie, Centre de Reference pour la SLA et les Maladies du Motoneurone, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, 47 Boulevard de l'Hôpital - F-75634, 13, Paris Cedex, France.
Claude DesnuellePôle Neurosciences - Service de Neurologie, Centre de Référence SLA et les maladies du neurone moteur, Hôpital Pasteur2, CHU de Nice Université Côte d'Azur, Nice, France.
French Kennedy’s Disease Writing Group
Sorbonne Université · FRCentre National de la Recherche Scientifique · FRCentre Hospitalier Universitaire de Tours · FRHôpital Cochin · FRHôpital Pasteur · FRInserm · FRTrinity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKennedy's disease (KD), also known as spinal and bulbar muscular atrophy (SBMA), is a rare, adult-onset, X-linked recessive neuromuscular disease caused by CAG expansions in exon 1 of the androgen receptor gene (AR). The objective of the French national diagnostic and management protocol is to provide evidence-based best practice recommendations and outline an optimised care pathway for patients with KD, based on a systematic literature review and consensus multidisciplinary observations.

resultsThe initial evaluation, confirmation of the diagnosis, and management should ideally take place in a tertiary referral centre for motor neuron diseases, and involve an experienced multidisciplinary team of neurologists, endocrinologists, cardiologists and allied healthcare professionals. The diagnosis should be suspected in an adult male presenting with slowly progressive lower motor neuron symptoms, typically affecting the lower limbs at onset. Bulbar involvement (dysarthria and dysphagia) is often a later manifestation of the disease. Gynecomastia is not a constant feature, but is suggestive of a suspected diagnosis, which is further supported by electromyography showing diffuse motor neuron involvement often with asymptomatic sensory changes. A suspected diagnosis is confirmed by genetic testing. The multidisciplinary assessment should ascertain extra-neurological involvement such as cardiac repolarisation abnormalities (Brugada syndrome), signs of androgen resistance, genitourinary abnormalities, endocrine and metabolic changes (glucose intolerance, hyperlipidemia). In the absence of effective disease modifying therapies, the mainstay of management is symptomatic support using rehabilitation strategies (physiotherapy and speech therapy). Nutritional evaluation by an expert dietician is essential, and enteral nutrition (gastrostomy) may be required. Respiratory management centres on the detection and treatment of bronchial obstructions, as well as screening for aspiration pneumonia (chest physiotherapy, drainage, positioning, breath stacking, mechanical insufflation-exsufflation, cough assist machnie, antibiotics). Non-invasive mechanical ventilation is seldom needed. Symptomatic pharmaceutical therapy includes pain management, endocrine and metabolic interventions. There is no evidence for androgen substitution therapy.

conclusionThe French national Kennedy's disease protocol provides management recommendations for patients with KD. In a low-incidence condition, sharing and integrating regional expertise, multidisciplinary experience and defining consensus best-practice recommendations is particularly important. Well-coordinated collaborative efforts will ultimately pave the way to the development of evidence-based international guidelines.

Indexed as

Bulbo-Spinal Atrophy, X-LinkedAdultElectromyographyGenetic TestingHumansMaleMotor NeuronsPractice Guidelines as TopicAndrogen insensitivityAndrogen receptorGuidelinesKennedy diseasePolyglutamineSpinal and bulbar muscular atrophy

Identifiers

PMID32276665
PMCPMC7149864
OpenAlexW3015510664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.